Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04096105 · ClinicalTrials.gov registry record · Phase 1

Japanese Pharmacokinetic Bridging Study for CC-93538

A Phase 1 study of Healthy Volunteers, sponsored by Celgene.

Completed
Registry status
Phase 1
Development phase
48
Enrollment target
1
Study location

NCT04096105 is a Phase 1 study of Healthy Volunteers that has completed, run by Celgene. The registered enrollment target is 48 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04096105, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Celgene.

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

This is an open-label, randomized, parallel design study to evaluate the PK, safety, tolerability and immunogenicity of single SC doses of CC-93538 in healthy Japanese and Caucasian adult subjects. A total of approximately 48 subjects, 24 Japanese and 24 Caucasians, will be enrolled. Japanese subjects will be enrolled first and randomized 1:1 to receive a single SC dose of either 180 mg or 360 mg CC-93538. Caucasian subjects will then be enrolled and matched to Japanese subjects (1:1) by weight (± 20%) and receive the same single SC dose of either 180 mg or 360 mg CC-93538.

Conditions Studied

Interventions

  • DRUG CC-93538

Study Locations (1)

California

  • Anaheim Clinical Trials - Anaheim

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2019-10-14
Est. Completion 2020-01-30
Phase Phase 1

Sponsor

Celgene

308 total trials

What the Registry Record Tells You About NCT04096105

The ClinicalTrials.gov registry entry for NCT04096105 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (90% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which CC-93538 is the first listed.

NCT04096105 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04096105 about?

NCT04096105 is a clinical study titled "Japanese Pharmacokinetic Bridging Study for CC-93538". This is an open-label, randomized, parallel design study to evaluate the PK, safety, tolerability and immunogenicity of single SC doses of CC-93538 in healthy Japanese and Caucasian adult subjects. A total of approximately 48 subjects, 24 Japanese and 24 Caucasians, will be enrolled. Japanese subje...

What is the current status of trial NCT04096105?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2019-10-14. Estimated completion is 2020-01-30.

What conditions does trial NCT04096105 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT04096105?

The interventions under investigation include: CC-93538 (DRUG).

Who is sponsoring clinical trial NCT04096105?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04096105 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.